Literature DB >> 27729254

Opioid dependence and pregnancy: minimizing stress on the fetal brain.

John J McCarthy1, Martin H Leamon2, Loretta P Finnegan3, Catherine Fassbender2.   

Abstract

Increase in the number of opioid-dependent pregnant women delivering babies at risk for neonatal abstinence syndrome prompted a US Government Accountability Office report documenting deficits in research and provider knowledge about care of the maternal/fetal unit and the neonate. There are 3 general sources of dependence: untreated opioid use disorder, pain management, and medication-assisted treatment with methadone or buprenorphine. A survey of methadone patients' experiences when telling a physician of their pregnancy and opioid dependence demonstrated physician confusion about proper care, frequent negative interactions with the mother, and failures to provide appropriate referral. Patients in pain management were discharged without referral when the physician was told of the pregnancy. Methadone and buprenorphine were frequently seen negatively because they "caused" neonatal abstinence syndrome. Most mothers surveyed had to find opioid treatment on their own. How dependence is managed medically is a critical determinant of the level of stress on both mother and fetus, and therefore another determinant of neonatal health. The effects of both opioid withdrawal stress and maternal emotional stress on neonatal and developmental outcomes are reviewed. Currently, there have been efforts to criminalize maternal opioid dependence and to encourage or coerce pregnant women to undergo withdrawal. This practice poses both acute risks of fetal hypoxia and long-term risks of adverse epigenetic programming related to catecholamine and corticosteroid surges during withdrawal. Contemporary studies of the effects of withdrawal stress on the developing fetal brain are urgently needed to elucidate and quantify the risks of such practices. At birth, inconsistencies in the hospital management of neonates at risk for neonatal abstinence syndrome have been observed. Neglect of the critical role of maternal comforting in neonatal abstinence syndrome management is an iatrogenic and preventable cause of poor outcomes and long hospitalizations. Rooming-in allows for continuous care of the baby and maternal/neonatal attachment, often unwittingly disrupted by the neonatal intensive care unit environment. Recommendations are made for further research into physician/patient interactions and into optimal dosing of methadone and buprenorphine to minimize maternal/fetal withdrawal.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  buprenorphine; fetal stress programming; methadone; neonatal abstinence syndrome; opioid dependence; pharmacokinetics; pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27729254     DOI: 10.1016/j.ajog.2016.10.003

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

1.  Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.

Authors:  Elizabeth E Krans; Joo Yeon Kim; Alton Everette James; David Kelley; Marian P Jarlenski
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

Review 2.  Effects of opioids on the parental brain in health and disease.

Authors:  James E Swain; S Shaun Ho; Helen Fox; David Garry; Susanne Brummelte
Journal:  Front Neuroendocrinol       Date:  2019-05-22       Impact factor: 8.606

3.  Management of opioid use disorders: a national clinical practice guideline.

Authors:  Julie Bruneau; Keith Ahamad; Marie-Ève Goyer; Ginette Poulin; Peter Selby; Benedikt Fischer; T Cameron Wild; Evan Wood
Journal:  CMAJ       Date:  2018-03-05       Impact factor: 8.262

4.  Early postpartum resting-state functional connectivity for mothers receiving buprenorphine treatment for opioid use disorder: A pilot study.

Authors:  James E Swain; S Shaun Ho
Journal:  J Neuroendocrinol       Date:  2019-07-29       Impact factor: 3.627

Review 5.  Gender Dynamics in Substance Use and Treatment: A Women's Focused Approach.

Authors:  Miriam T H Harris; Jordana Laks; Natalie Stahl; Sarah M Bagley; Kelley Saia; Wendee M Wechsberg
Journal:  Med Clin North Am       Date:  2022-01       Impact factor: 5.456

6.  Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy.

Authors:  Sugy Choi; Michael D Stein; Julia Raifman; David Rosenbloom; Jack A Clark
Journal:  Drug Alcohol Depend       Date:  2021-10-29       Impact factor: 4.492

7.  Opioids affect the fetal brain: reframing the detoxification debate.

Authors:  Steve N Caritis; Ashok Panigrahy
Journal:  Am J Obstet Gynecol       Date:  2019-07-16       Impact factor: 8.661

8.  Characterization of neonatal opioid withdrawal syndrome in Arizona from 2010-2017.

Authors:  Emery R Eaves; Jarrett Barber; Ryann Whealy; Sara A Clancey; Rita Wright; Jill Hager Cocking; Joseph Spadafino; Crystal M Hepp
Journal:  PLoS One       Date:  2021-06-03       Impact factor: 3.752

9.  Prenatal methadone exposure is associated with altered neonatal brain development.

Authors:  Victoria J Monnelly; Devasuda Anblagan; Alan Quigley; Manuel Blesa Cabez; E Sarah Cooper; Helen Mactier; Scott I Semple; Mark E Bastin; James P Boardman
Journal:  Neuroimage Clin       Date:  2017-12-24       Impact factor: 4.881

10.  Barriers and Motivators to Opioid Treatment Among Suburban Women Who Are Pregnant and Mothers in Caregiver Roles.

Authors:  Miriam Boeri; Aukje K Lamonica; Jeffrey M Turner; Amanda Parker; Grace Murphy; Carly Boccone
Journal:  Front Psychol       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.